Cargando…

Hemopatch(®) as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation

INTRODUCTION: Partial nephrectomy (PN) has evolved into the surgical standard of care for localized renal lesions. Hemostatic agents (HA) support the surgeon in achieving local hemostasis during PN. We previously reported initial results with the HA Hemopatch(®) in PN. We now report our experiences...

Descripción completa

Detalles Bibliográficos
Autores principales: Hupe, Marie C., Büttner, Maximilian, Tabrizi, Pouriya Faraj, Merseburger, Axel S., Kuczyk, Markus A., Imkamp, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889526/
https://www.ncbi.nlm.nih.gov/pubmed/33277680
http://dx.doi.org/10.1007/s12325-020-01584-8
_version_ 1783652329037234176
author Hupe, Marie C.
Büttner, Maximilian
Tabrizi, Pouriya Faraj
Merseburger, Axel S.
Kuczyk, Markus A.
Imkamp, Florian
author_facet Hupe, Marie C.
Büttner, Maximilian
Tabrizi, Pouriya Faraj
Merseburger, Axel S.
Kuczyk, Markus A.
Imkamp, Florian
author_sort Hupe, Marie C.
collection PubMed
description INTRODUCTION: Partial nephrectomy (PN) has evolved into the surgical standard of care for localized renal lesions. Hemostatic agents (HA) support the surgeon in achieving local hemostasis during PN. We previously reported initial results with the HA Hemopatch(®) in PN. We now report our experiences with Hemopatch(®) in a larger and more challenging single-surgeon PN cohort. METHODS: Our study included 45 patients who underwent PN due to suspicious renal lesions between December 2013 and March 2018. All surgeries were performed by a single surgeon using the HA Hemopatch(®). Preoperative, intraoperative, and postoperative parameters were assessed. RESULTS: Preoperative median tumor diameter was 27 mm. Median PADUA and RENAL nephrometry scores were 7 and 6, respectively. In 13.3% of the cases an additional HA was applied. Intraoperative and postoperative bleeding occurred in 2.2% and 8.9%, respectively. Median total blood loss was 200 ml. Urgent pedicle clamping due to bleeding was necessary in 2 (4.4%) patients. The transfusion rate was 8.9%. There were no conversions. CONCLUSION: We confirmed our initial results demonstrating feasibility and reliability of Hemopatch(®) during PN. Notably, the cohort consists of selected patients. Prospective randomized studies are needed for comparison of different types of HA with regard to perioperative outcome.
format Online
Article
Text
id pubmed-7889526
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-78895262021-03-03 Hemopatch(®) as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation Hupe, Marie C. Büttner, Maximilian Tabrizi, Pouriya Faraj Merseburger, Axel S. Kuczyk, Markus A. Imkamp, Florian Adv Ther Original Research INTRODUCTION: Partial nephrectomy (PN) has evolved into the surgical standard of care for localized renal lesions. Hemostatic agents (HA) support the surgeon in achieving local hemostasis during PN. We previously reported initial results with the HA Hemopatch(®) in PN. We now report our experiences with Hemopatch(®) in a larger and more challenging single-surgeon PN cohort. METHODS: Our study included 45 patients who underwent PN due to suspicious renal lesions between December 2013 and March 2018. All surgeries were performed by a single surgeon using the HA Hemopatch(®). Preoperative, intraoperative, and postoperative parameters were assessed. RESULTS: Preoperative median tumor diameter was 27 mm. Median PADUA and RENAL nephrometry scores were 7 and 6, respectively. In 13.3% of the cases an additional HA was applied. Intraoperative and postoperative bleeding occurred in 2.2% and 8.9%, respectively. Median total blood loss was 200 ml. Urgent pedicle clamping due to bleeding was necessary in 2 (4.4%) patients. The transfusion rate was 8.9%. There were no conversions. CONCLUSION: We confirmed our initial results demonstrating feasibility and reliability of Hemopatch(®) during PN. Notably, the cohort consists of selected patients. Prospective randomized studies are needed for comparison of different types of HA with regard to perioperative outcome. Springer Healthcare 2020-12-04 2021 /pmc/articles/PMC7889526/ /pubmed/33277680 http://dx.doi.org/10.1007/s12325-020-01584-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Hupe, Marie C.
Büttner, Maximilian
Tabrizi, Pouriya Faraj
Merseburger, Axel S.
Kuczyk, Markus A.
Imkamp, Florian
Hemopatch(®) as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation
title Hemopatch(®) as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation
title_full Hemopatch(®) as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation
title_fullStr Hemopatch(®) as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation
title_full_unstemmed Hemopatch(®) as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation
title_short Hemopatch(®) as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation
title_sort hemopatch(®) as a hemostatic agent is safe in partial nephrectomy: a large, single-surgeon retrospective evaluation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889526/
https://www.ncbi.nlm.nih.gov/pubmed/33277680
http://dx.doi.org/10.1007/s12325-020-01584-8
work_keys_str_mv AT hupemariec hemopatchasahemostaticagentissafeinpartialnephrectomyalargesinglesurgeonretrospectiveevaluation
AT buttnermaximilian hemopatchasahemostaticagentissafeinpartialnephrectomyalargesinglesurgeonretrospectiveevaluation
AT tabrizipouriyafaraj hemopatchasahemostaticagentissafeinpartialnephrectomyalargesinglesurgeonretrospectiveevaluation
AT merseburgeraxels hemopatchasahemostaticagentissafeinpartialnephrectomyalargesinglesurgeonretrospectiveevaluation
AT kuczykmarkusa hemopatchasahemostaticagentissafeinpartialnephrectomyalargesinglesurgeonretrospectiveevaluation
AT imkampflorian hemopatchasahemostaticagentissafeinpartialnephrectomyalargesinglesurgeonretrospectiveevaluation